CN111743856B - A kind of triptolide ophthalmic material and preparation method and application thereof - Google Patents
A kind of triptolide ophthalmic material and preparation method and application thereof Download PDFInfo
- Publication number
- CN111743856B CN111743856B CN202010516077.XA CN202010516077A CN111743856B CN 111743856 B CN111743856 B CN 111743856B CN 202010516077 A CN202010516077 A CN 202010516077A CN 111743856 B CN111743856 B CN 111743856B
- Authority
- CN
- China
- Prior art keywords
- triptolide
- carboxymethyl chitosan
- ophthalmic material
- nano
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 title claims abstract description 101
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 title claims abstract description 97
- 239000000463 material Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 48
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000725 suspension Substances 0.000 claims abstract description 25
- 239000010949 copper Substances 0.000 claims abstract description 24
- 229910052802 copper Inorganic materials 0.000 claims abstract description 24
- 238000003756 stirring Methods 0.000 claims abstract description 24
- 229920001661 Chitosan Polymers 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 8
- -1 aldehyde benzyl ester Chemical class 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 39
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 23
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000499 gel Substances 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 239000005711 Benzoic acid Substances 0.000 claims description 11
- 235000010233 benzoic acid Nutrition 0.000 claims description 11
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 238000007711 solidification Methods 0.000 claims description 8
- 230000008023 solidification Effects 0.000 claims description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical class [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 239000012044 organic layer Substances 0.000 claims description 7
- 238000010898 silica gel chromatography Methods 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000004809 thin layer chromatography Methods 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 claims 2
- GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 claims 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 2
- 241000830536 Tripterygium wilfordii Species 0.000 claims 1
- 235000015398 thunder god vine Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 6
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 abstract description 4
- 229910001431 copper ion Inorganic materials 0.000 abstract description 4
- 239000002262 Schiff base Substances 0.000 abstract description 3
- 125000003172 aldehyde group Chemical group 0.000 abstract description 3
- 125000003277 amino group Chemical group 0.000 abstract description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000011866 long-term treatment Methods 0.000 abstract 1
- 150000004702 methyl esters Chemical class 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 229940014800 succinic anhydride Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 229940079593 drug Drugs 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 238000009210 therapy by ultrasound Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000007227 biological adhesion Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 206010011017 Corneal graft rejection Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004453 corneal transparency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002740 effect on eyes Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种雷公藤甲素眼科材料及其制备方法与应用。所述方法为：(1)雷公藤甲素与丁二酸酐和4‑二甲氨基吡啶反应，得到雷公藤甲素丁二酸单酯；(2)将羧甲基壳聚糖与雷公藤甲素对醛基苯甲酯混合制备羧甲基壳聚糖‑雷公藤甲素对醛基苯甲酯溶液；(3)将纳米铜悬浊液加入羧甲基壳聚糖‑雷公藤甲素对醛基苯甲酯溶液中，搅拌，静置，得到雷公藤甲素眼科材料。本发明通过制备雷公藤甲素对醛基苯甲酯，利用其醛基与羧甲基壳聚糖上的氨基作用形成动态键席夫碱键，使其在治疗时容易脱落，发挥疗效。辅以铜离子与羧甲基壳聚糖螯合成凝胶，减弱了雷公藤甲素的毒性，改善溶解性，还提高其生物利用度，达到延长其半衰期，从而长效治疗的效果。The invention discloses a triptolide ophthalmic material and a preparation method and application thereof. The method is as follows: (1) reacting triptolide with succinic anhydride and 4-dimethylaminopyridine to obtain triptolide succinate monoester; (2) reacting carboxymethyl chitosan with triptolide The carboxymethyl chitosan-triptolide-p-formylbenzyl methyl ester solution was prepared by mixing carboxymethyl chitosan-triptolide; (3) adding the nano-copper suspension to the carboxymethyl chitosan-triptolide In the aldehyde benzyl ester solution, stirring and standing, the triptolide ophthalmic material is obtained. The invention prepares triptolide p-formylbenzyl, utilizes the interaction between its aldehyde group and the amino group on carboxymethyl chitosan to form a dynamic bond Schiff base bond, so that it is easy to fall off during treatment and exerts a curative effect. Supplemented by copper ions and carboxymethyl chitosan chelated into gel, the toxicity of triptolide is weakened, the solubility is improved, and its bioavailability is improved, so as to prolong its half-life, so as to achieve the effect of long-term treatment.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a triptolide ophthalmic material as well as a preparation method and application thereof.
Background
With the continuous improvement of medical level, the success rate of corneal transplantation is greatly improved in the current clinical treatment of ophthalmology. However, based on the current medical apparatus and medical level, although the inflammatory complications caused by corneal transplantation are relatively easy to control, the subsequent autoimmune rejection is a key reason for the failure of the surgery. The current major methods for treating post-operative immune rejection include systemic use of corticosteroid hormones, use of corticosteroid eye drops, and some other novel anti-immune rejection formulations. Although the use of corticosteroid hormones can be effective in producing an anti-immune rejection effect, the side effects on the body are still very serious. Therefore, the development of new immunosuppressive drugs is imminent. Triptolide has been proved in current scientific research and clinical organ transplantation to have the functions of preventing graft-versus-host disease and effectively prolonging the survival time of host. However, triptolide has the disadvantages of strong toxicity, poor water solubility and the like, and greatly limits the clinical application of triptolide. In view of the above, it is considered that the triptolide is physically or chemically treated to reduce its toxicity, and then combined with other substances to achieve better therapeutic effect. At present, a plurality of scientific researchers carry out chemical modification on triptolide, generally, the triptolide is directly grafted to a high molecular polymer with good biocompatibility, although the water solubility of the triptolide is improved to some extent, the toxicity of the triptolide is also reduced, when the triptolide is applied to treatment, the triptolide with small molecular weight is difficult to fall off from the high molecular polymer, and the drug effect is difficult to exert. In addition, clinically, triptolide is administrated in the form of eye drops, although the preparation process is simple, the administration is convenient, and the effect is rapid, the drug exists in the form of solution and has no biological adhesion, so that the triptolide is easily diluted by tears and is discharged from lacrimal passages along with the tears, the bioavailability is low, and meanwhile, the action time of the drug is very short, which means that the frequent administration is needed, and the inconvenience is very high. Therefore, the triptolide is subjected to simple chemical structure modification, and then gel is taken as a material carrier to achieve the effects of synergy and attenuation, so that the long-acting sustained-release triptolide ophthalmic material for preventing corneal transplantation rejection is prepared, and a new treatment option is provided for clinical prevention of corneal transplantation rejection.
Disclosure of Invention
In order to overcome the defects and shortcomings in the prior art, the invention mainly aims to provide a preparation method of a triptolide ophthalmic material.
The preparation method comprises the steps of carrying out structural modification on triptolide by a chemical means, carrying out esterification reaction on hydroxyl of the triptolide and carboxyl of p-aldehyde benzoic acid with small molecular weight to generate triptolide p-aldehyde benzyl ester, forming a dynamic bond Schiff base bond by utilizing the action of the aldehyde group of the triptolide p-aldehyde benzyl ester and amino of carboxymethyl chitosan with good biocompatibility, and chelating copper ions released by nano-copper and the carboxyl of the carboxymethyl chitosan to form gel, thereby obtaining the triptolide ophthalmic material. The triptolide ophthalmic material has good biological safety, low toxicity, long-acting slow release and high bioavailability.
The other purpose of the invention is to provide the triptolide ophthalmic material prepared by the preparation method.
The invention also aims to provide application of the triptolide ophthalmic material.
A preparation method of triptolide ophthalmic material comprises the following steps:
(1) dissolving triptolide in a solvent, adding p-aldehyde benzoic acid and 4-Dimethylaminopyridine (DMAP) under the protection of nitrogen, reacting at room temperature, and purifying to obtain triptolide p-aldehyde benzyl ester;
(2) uniformly mixing carboxymethyl chitosan and triptolide p-aldehyde benzyl ester, adding water, stirring to uniformly disperse and completely dissolve the mixture to obtain carboxymethyl chitosan-triptolide p-aldehyde benzyl ester solution; putting the nano copper powder in water, performing ultrasonic treatment, and uniformly dispersing to form a nano copper suspension;
(3) adding the nano-copper suspension into carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution under stirring, standing to form gel, and solidifying to obtain triptolide ophthalmic material.
Preferably, the solvent in step (1) is at least one of pyridine, dimethyl sulfoxide, tetrahydrofuran and dimethylformamide.
Preferably, the room temperature in the step (1) is 25 ℃, and the reaction time is 24-36 h.
Preferably, the molar ratio of triptolide to p-aldehyde benzoic acid in the step (1) is 1: (1-2), namely the mass ratio of the triptolide to the p-aldehyde benzoic acid is 108: (45-90).
Preferably, the mass ratio of the triptolide to the 4-dimethylaminopyridine in the step (1) is (18-24): 1.
preferably, the ratio of the triptolide and the solvent in the step (1) is 10.8-21.6 mg/ml.
Preferably, the purification method in step (1) is: and (2) performing thin-layer chromatography (petroleum ether: ethyl acetate: 1: 5-10) on the mixed product, then adding excessive ethyl acetate for dilution, then washing with saturated copper sulfate solution and sodium chloride aqueous solution in sequence, separating and purifying to obtain an organic layer, then drying with anhydrous sodium sulfate, filtering to obtain a filtrate, concentrating, and finally purifying by silica gel column chromatography (dichloromethane/methanol, 10-15: 1) to obtain pure triptolide p-formyl benzyl ester.
Preferably, the mass ratio of the carboxymethyl chitosan to the triptolide p-aldehyde benzyl ester in the step (2) is 20-80: 1.
preferably, in the carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution in the step (2), the concentration of the carboxymethyl chitosan is 2-4 wt%, and the concentration of the triptolide p-formaldehyde benzyl ester is 0.5-1 mg/ml.
Preferably, the rotation speed of the water adding and stirring in the step (2) is 800-1200 rpm, and the time is 3-6 h; the ultrasonic time is 15-30 min.
Preferably, in the nano-copper suspension in the step (2), the ratio of the nano-copper to the water is 1.5-3 mg/ml.
Preferably, the volume ratio of the nano-copper suspension in the step (3) to the carboxymethyl chitosan-triptolide-p-formaldehyde benzyl ester solution is 1: (4.5-9).
Preferably, the adding in the step (3) refers to dropwise adding the nano-copper suspension into the carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution within 10-20 min.
Preferably, the stirring speed in the step (3) is 500-1000 rpm, and the time is 5-10 h; the standing time is 24-36 h.
Preferably, the nano-copper suspension and the carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution in the step (3) are stirred and kept stand to form a gel state, then the gel state is filled into a syringe with a needle for extrusion injection, and after solidification, the gel state is cut into a small rod shape, wherein the diameter of the small rod shape is 0.01-0.1 cm, and the length of the small rod shape is 0.2-0.5 cm.
The triptolide ophthalmic material prepared by the method.
The application of the triptolide ophthalmic material is provided.
Preferably, the triptolide ophthalmic material is applied to pharmaceutical preparations.
The carboxymethyl chitosan is a biological high molecular polymer, has no stimulation, good biocompatibility, biological adhesion and biodegradability, has no toxicity of degradation products, can be completely absorbed by organisms, and is widely concerned as an ideal drug carrier. The research shows that a small amount of copper ions have no stimulation and toxic or side effect on eyes. The invention generates triptolide p-aldehyde benzyl ester by using the esterification reaction of triptolide hydroxyl and carboxyl of p-aldehyde benzoic acid with small molecular weight, and then forms a dynamic Schiff base bond by using the action of the aldehyde group of the triptolide p-aldehyde benzyl ester and the self-carried amino group of carboxymethyl chitosan with good biocompatibility, so that the triptolide p-aldehyde benzyl ester can easily fall off during treatment, and the curative effect can be exerted. And then the copper ions released by the nano-copper are chelated with the carboxyl of the carboxymethyl chitosan to form gel, so as to obtain the triptolide ophthalmic material. The toxicity of the medicine is weakened, the defect of poor solubility is improved, the bioavailability of the medicine is improved, and the half-life period of the medicine is prolonged, so that the long-acting treatment effect is achieved.
Compared with the prior art, the invention has the following advantages and beneficial effects:
(1) the triptolide ophthalmic material prepared by the invention has good biological safety, and the triptolide drug micromolecules are easy to fall off from the carrier so as to exert the drug effect, and the bioavailability is high.
(2) The triptolide ophthalmic material prepared by the invention has the advantages of abundant and easily obtained raw materials, simple production process of the product and easy preparation.
(3) The triptolide ophthalmic material prepared by the invention can be used as a novel pharmaceutical preparation to be applied to clinically preventing corneal transplantation rejection, reducing the administration frequency, having good curative effect and wide application value.
Drawings
Fig. 1 is a scanning electron microscope image of the triptolide ophthalmic material obtained in example 1.
Fig. 2 is a diagram of the triptolide ophthalmic materials of different proportions obtained in example 6.
Fig. 3 is a graph showing the drug sustained-release effect of the triptolide ophthalmic material obtained in example 1.
Fig. 4 is a graph showing the results of animal experiments on the triptolide ophthalmic material obtained in example 1.
Detailed Description
The present invention will be described in further detail with reference to examples and drawings, but the embodiments of the present invention are not limited thereto.
Those who do not specify specific conditions in the examples of the present invention follow conventional conditions or conditions recommended by the manufacturer. The raw materials, reagents and the like which are not indicated for manufacturers are all conventional products which can be obtained by commercial purchase.
Example 1
(1) Dissolving 108mg triptolide in 5ml pyridine, adding 45mg p-aldehyde benzoic acid and 6mg 4-Dimethylaminopyridine (DMAP) under the protection of nitrogen, reacting for 24h at room temperature and 25 ℃, taking a mixed product, carrying out thin-layer chromatography (petroleum ether: ethyl acetate: 1: 5), then adding excessive ethyl acetate for dilution, still washing with a saturated copper sulfate solution and a sodium chloride aqueous solution, separating and purifying to obtain an organic layer, then drying with anhydrous sodium sulfate, filtering to obtain a filtrate, concentrating, and finally purifying by silica gel column chromatography (dichloromethane/methanol, 10: 1) to obtain triptolide p-aldehyde benzyl ester;
(2) uniformly mixing 0.4g of carboxymethyl chitosan powder with 10mg of triptolide p-formaldehyde benzyl ester, adding 18ml of water, stirring at the rotating speed of 800rpm for 3 hours to uniformly disperse and completely dissolve the mixture to obtain carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution; putting 4mg of nano copper powder in 2ml of water, performing ultrasonic treatment for 15min, and uniformly dispersing to form a suspension;
(3) and (3) adding 2ml of the nano-copper suspension prepared in the step (2) into 18ml of carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution within 10min under the stirring state at the rotating speed of 500rpm, stirring for 5h, standing for 24h to form a gel state, putting into a syringe with a needle head, extruding and injecting, and cutting into a small rod shape with the diameter of 0.1mm and the length of 2mm after solidification to obtain the triptolide ophthalmic material.
Example 2
(1) Dissolving 108mg triptolide in 5ml dimethyl sulfoxide, adding 90mg p-aldehyde benzoic acid and 4.5mg 4-Dimethylaminopyridine (DMAP) under the protection of nitrogen, reacting at room temperature of 25 ℃ for 36h, taking a mixed product, carrying out thin-layer chromatography (petroleum ether: ethyl acetate: 1: 10), then adding excessive ethyl acetate for dilution, still washing with a saturated copper sulfate solution and a sodium chloride aqueous solution, separating and purifying to obtain an organic layer, then drying with anhydrous sodium sulfate, filtering to obtain a filtrate, concentrating, and finally purifying by silica gel column chromatography (dichloromethane/methanol, 15: 1) to obtain triptolide p-aldehyde benzyl ester;
(2) uniformly mixing 0.8g of carboxymethyl chitosan powder with 20mg of triptolide p-formaldehyde benzyl ester, adding 18ml of water, stirring at the rotating speed of 1200rpm for 6 hours to uniformly disperse and completely dissolve the mixture to obtain carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution; putting 6mg of nano copper powder in 4ml of water, performing ultrasonic treatment for 30min, and uniformly dispersing to form a suspension;
(3) and (3) adding 4ml of the nano-copper suspension prepared in the step (2) into 18ml of carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution within 20min under the stirring state at the rotating speed of 1000rpm, stirring for 10h, standing for 36h to form a gel state, putting into a syringe with a needle head, extruding and injecting, and cutting into a small rod with the diameter of 1mm and the length of 5mm after solidification to obtain the triptolide ophthalmic material.
Example 3
(1) Dissolving 108mg triptolide in 5ml tetrahydrofuran, adding 68mg p-aldehyde benzoic acid and 5mg 4-Dimethylaminopyridine (DMAP) under the protection of nitrogen, reacting at room temperature of 25 ℃ for 30h, taking a mixed product, carrying out thin-layer chromatography (petroleum ether: ethyl acetate: 1: 7), then adding excessive ethyl acetate for dilution, still washing with a saturated copper sulfate solution and a sodium chloride aqueous solution, separating and purifying to obtain an organic layer, then drying with anhydrous sodium sulfate, filtering to obtain a filtrate, concentrating, and finally purifying by silica gel column chromatography (dichloromethane/methanol, 12: 1) to obtain triptolide p-aldehyde benzyl ester;
(2) uniformly mixing 0.6g of carboxymethyl chitosan powder with 15mg of triptolide p-aldehyde benzyl ester, adding 18ml of water, stirring at the rotating speed of 1000rpm for 4.5 hours to uniformly disperse and completely dissolve the carboxymethyl chitosan-triptolide p-aldehyde benzyl ester solution to obtain a carboxymethyl chitosan-triptolide p-aldehyde benzyl ester solution; putting 5mg of nano copper powder in 3ml of water, performing ultrasonic treatment for 23min, and uniformly dispersing to form a suspension;
(3) and (3) adding the 3ml of nano-copper suspension prepared in the step (2) into 18ml of carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution within 15min under the stirring state with the rotation speed of 750rpm, stirring for 7.5h, standing for 30h to form a gel state, filling into a syringe with a needle head, extruding and injecting to solidify, and shearing into a small rod with the diameter of 0.5mm and the length of 3.5mm to obtain the triptolide ophthalmic material.
Example 4
(1) Dissolving 108mg triptolide in 5ml dimethylformamide, adding 45mg p-aldehyde benzoic acid and 6mg 4-Dimethylaminopyridine (DMAP) under the protection of nitrogen, reacting at room temperature of 25 ℃ for 24h, taking a mixed product, carrying out thin-layer chromatography (petroleum ether: ethyl acetate is 1: 10), then adding excessive ethyl acetate for dilution, still washing with a saturated copper sulfate solution and a sodium chloride aqueous solution, separating and purifying to obtain an organic layer, then drying with anhydrous sodium sulfate, filtering to obtain a filtrate, concentrating, and finally purifying by silica gel column chromatography (dichloromethane/methanol, 10: 1) to obtain triptolide p-aldehyde benzyl ester;
(2) uniformly mixing 0.8g of carboxymethyl chitosan powder with 10mg of triptolide p-formaldehyde benzyl ester, adding 18ml of water, stirring at the rotating speed of 1200rpm for 3 hours to uniformly disperse and completely dissolve the carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution to obtain a carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution; putting 6mg of nano copper powder in 2ml of water, performing ultrasonic treatment for 15min, and uniformly dispersing to form a suspension;
(3) and (3) adding 2ml of the nano-copper suspension prepared in the step (2) into 18ml of carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution within 10min under the stirring state at the rotating speed of 1000rpm, stirring for 10h, standing for 24h to form a gel state, putting into a syringe with a needle head, extruding and injecting, and cutting into a small rod with the diameter of 0.1mm and the length of 5mm after solidification to obtain the triptolide ophthalmic material.
Example 5
(1) Dissolving 108mg triptolide in 5ml pyridine, adding 90mg p-aldehyde benzoic acid and 4.5mg 4-Dimethylaminopyridine (DMAP) under the protection of nitrogen, reacting at room temperature of 25 ℃ for 36h, taking a mixed product, carrying out thin-layer chromatography (petroleum ether: ethyl acetate: 1: 5), then adding excessive ethyl acetate for dilution, still washing with a saturated copper sulfate solution and a sodium chloride aqueous solution, separating and purifying to obtain an organic layer, then drying with anhydrous sodium sulfate, filtering to obtain a filtrate, concentrating, and finally purifying by silica gel column chromatography (dichloromethane/methanol, 15: 1) to obtain triptolide p-aldehyde benzyl ester;
(2) uniformly mixing 0.4g of carboxymethyl chitosan powder with 20mg of triptolide p-formaldehyde benzyl ester, adding 18ml of water, stirring at the rotating speed of 1200rpm for 3 hours to uniformly disperse and completely dissolve the carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution to obtain a carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution; putting 6mg of nano copper powder in 4ml of water, performing ultrasonic treatment for 30min, and uniformly dispersing to form a suspension;
(3) and (3) under the stirring state with the rotation speed of 500rpm, adding 4ml of the nano-copper suspension prepared in the step (2) into 18ml of carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution within 20min, stirring for 5h, standing for 36h to form a gel state, putting into a syringe with a needle head, extruding and injecting, after solidification, shearing into a small rod shape with the diameter of 1mm and the length of 2mm, and obtaining the triptolide ophthalmic material.
Example 6
Under the same condition as that of the other conditions of the embodiment 1, nano-copper suspension liquid (the concentration is respectively 2mg/ml, 0.1mg/ml and 6mg/ml) with different concentrations is added into carboxymethyl chitosan-triptolide p-formaldehyde benzyl ester solution, the solution is stirred and kept stand to form a gel state, the gel state is filled into the same syringe with a needle head to be extruded and injected, and after solidification, the three are extruded and injected, in order to compare the strength and the toughness of the three more intuitively, the three are not sheared, and when the eye is implanted, the three are sheared into a small bar shape, the size diameter of the small bar is 0.1mm-1mm, and the length of the small bar is 2-5 mm, so that different triptolide ophthalmic materials are obtained.
As shown in figure 2, the concentration of the nano-copper suspension added in the group a is 2mg/ml, the concentration of the group b and the concentration of the group c are respectively 0.1mg/ml and 6mg/ml, and compared with the three groups, the group a can still recover after being folded in half, and the group b and the group c can be broken and have poor toughness; and the surface of a is smoother, and the surfaces of b and c are similar to flocculent fibers, so that sticky tissues are easily caused. In fig. 1, the electron microscope image also shows that a has a smooth surface, so that the group a is more suitable for being implanted into the eye.
Example 7 drug Release test
The triptolide ophthalmic material prepared according to the method of example 1 was put into a dialysis bag (MWCO ═ 2000Da), and was shaken in a 0.01mol/L PBS solution (phosphate buffer solution) having a pH of 7.4 at 37 ℃ in a shaker, 2mL of the above PBS solution containing the drug was periodically taken out, and 2mL of fresh PBS solution was immediately added, and the light absorption value of the taken solution (PBS solution containing the drug) was measured to investigate the drug sustained-release rule.
As shown in fig. 3, the release process of the drug can be divided into three stages, wherein the drug is released quickly in the first stage for 0-72 hours, and the cumulative release rate reaches 31%; the second stage is a zero-order release stage of the drug within 72-450 hours, and the cumulative release rate of the drug reaches 53%; the third stage of drug release is 450 hours later, the drug release rate begins to slow down, and finally reaches equilibrium in 504 hours, and the cumulative release rate is 56%; the slow release of the medicine can be obtained, and the medicine finally tends to be stable and has long-acting slow release effect.
EXAMPLE 8 animal experiments on corneal graft rejection
SD rats subjected to corneal transplantation were randomly divided into 2 groups of 30 animals each, one experimental group in which the triptolide ophthalmic material prepared in example 1 was immediately implanted after surgery, and one control group to which physiological saline was added. And observing with slit lamp microscope for 1 time every 2 days from 3 days after operation, observing corneal rejection with corneal transparency, edema degree, and neovascularization degree as indexes, killing 3 rats per group 2 weeks after operation, taking eyeball, performing HE staining, and observing neovascularization condition.
As shown in fig. 4, the left graph is the result graph of the control group, the right graph is the result graph of the experimental group, and the eyeballs of the mice are observed, compared with the control group, the neogenesis blood vessels of the palpebral conjunctiva and the bulbar conjunctiva of the experimental group are reduced, so that the slow-release triptolide of the material plays a role in exerting the drug effect, and the corneal transplantation rejection of the mice is improved.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010516077.XA CN111743856B (en) | 2020-06-09 | 2020-06-09 | A kind of triptolide ophthalmic material and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010516077.XA CN111743856B (en) | 2020-06-09 | 2020-06-09 | A kind of triptolide ophthalmic material and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111743856A CN111743856A (en) | 2020-10-09 |
| CN111743856B true CN111743856B (en) | 2021-07-23 |
Family
ID=72674997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010516077.XA Active CN111743856B (en) | 2020-06-09 | 2020-06-09 | A kind of triptolide ophthalmic material and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111743856B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1431336A (en) * | 1973-04-03 | 1976-04-07 | Kupchan S M | Diterpenoid triepoxides their isolation and use |
| CA2277564A1 (en) * | 1999-07-13 | 2001-01-13 | Takagi, Tomofumi | Inhibiting agent against platelet-derived growth factor increase and arteriosclerosis preventive and therapeutic agent |
| US6548537B1 (en) * | 1998-09-02 | 2003-04-15 | Pharmagenesis, Inc. | Triptolide prodrugs having high aqueous solubility |
| CN105560253A (en) * | 2014-10-10 | 2016-05-11 | 金陈进 | Use of compound triptolide in choroidal neovascularization |
| CN106380609A (en) * | 2016-09-19 | 2017-02-08 | 天津科技大学 | Antibacterial carboxymethyl chitosan hydrogel and preparation method thereof |
| CN107964105A (en) * | 2017-11-08 | 2018-04-27 | 福州大学 | A kind of preparation method by the crosslinked polysaccharide based aquagel of dynamic imine linkage |
| CN109464675A (en) * | 2018-11-29 | 2019-03-15 | 河南中医药大学 | A kind of preparation method and application of triptolide-carboxylated chitosan conjugated drug |
-
2020
- 2020-06-09 CN CN202010516077.XA patent/CN111743856B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1431336A (en) * | 1973-04-03 | 1976-04-07 | Kupchan S M | Diterpenoid triepoxides their isolation and use |
| US6548537B1 (en) * | 1998-09-02 | 2003-04-15 | Pharmagenesis, Inc. | Triptolide prodrugs having high aqueous solubility |
| CA2277564A1 (en) * | 1999-07-13 | 2001-01-13 | Takagi, Tomofumi | Inhibiting agent against platelet-derived growth factor increase and arteriosclerosis preventive and therapeutic agent |
| CN105560253A (en) * | 2014-10-10 | 2016-05-11 | 金陈进 | Use of compound triptolide in choroidal neovascularization |
| CN106380609A (en) * | 2016-09-19 | 2017-02-08 | 天津科技大学 | Antibacterial carboxymethyl chitosan hydrogel and preparation method thereof |
| CN107964105A (en) * | 2017-11-08 | 2018-04-27 | 福州大学 | A kind of preparation method by the crosslinked polysaccharide based aquagel of dynamic imine linkage |
| CN109464675A (en) * | 2018-11-29 | 2019-03-15 | 河南中医药大学 | A kind of preparation method and application of triptolide-carboxylated chitosan conjugated drug |
Non-Patent Citations (4)
| Title |
|---|
| "Novel Carboxylated Chitosan-Based Triptolide Conjugate for the Treatment of Rheumatoid Arthritis";Lan Zhang et al.;《Pharmaceutics》;20200226;第12卷;第1-13页 * |
| "Preparation and antibacterial activity of Schiff bases from O-carboxymethyl chitosan and para-substituted benzaldehydes";Xueqiong Yin et al.;《Polym. Bull.》;20110820;第68卷;第1215-1226页 * |
| "Synthesis and characterization of water soluble O-carboxymethylchitosan Schiff bases and Cu(II) complexes";Talat Baran et al.;《International Journal of Biological Macromolecules》;20140813;第72卷;第94-103页 * |
| "Synthesis and In Vitro Characterization of Carboxymethyl Chitosan-CBA-Doxorubicin Conjugate Nanoparticles as pH-Sensitive Drug Delivery Systems";Rui Hu et al.;《Journal of Biomedical Nanotechnology》;20171231;第13卷(第9期);第1097-1105页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111743856A (en) | 2020-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7332205B2 (en) | Polycaprolactone microsphere filler containing vitamin C and method for producing the same | |
| DE3650776T2 (en) | Polysaccharide esters and their salts | |
| EP1248596B1 (en) | Implantation kit comprising a support phase and a solvent | |
| JPH10324701A (en) | Crosslinked carboxypolysaccharide | |
| CN110664757B (en) | Nanocrystalline eye drop, preparation method and application thereof | |
| Li et al. | Soft freezing-induced self-assembly of silk fibroin for tunable gelation | |
| CN102670518B (en) | Preparation method for insoluble spherical medical granules | |
| JP5413998B2 (en) | Inclusion complex of pinocembrin by cyclodextrin or its derivatives | |
| JP2010514707A (en) | Use of a hypertonic solution composition for the manufacture of a drug that promotes wound healing | |
| CN101868232B (en) | Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same | |
| JP3282729B2 (en) | Self-crosslinked gellan gum | |
| KR101468153B1 (en) | 5α-ANDROSTANE-3β,5,6β-TRIOL INJECTION AND PREPARATION METHOD THEREFOR | |
| CN111743856B (en) | A kind of triptolide ophthalmic material and preparation method and application thereof | |
| US2857312A (en) | Esters of erythromycin and carbomycin | |
| CN102481287A (en) | Pharmaceutical composition of temozolomide comprising vitamin c or vitamin c derivative and preparation method thereof | |
| CN116407509B (en) | Riagliptin long-acting sustained-release microsphere and preparation method thereof | |
| CN108969797A (en) | A kind of load lipidosome gel and preparation method thereof with electro photoluminescence and the neural scar effect of inhibition | |
| CN101756954A (en) | Schneiderian membrane medication preparation of isosorbide dinitrate and preparation method thereof | |
| JP7623953B2 (en) | Pharmaceutical or cosmetic compositions | |
| JP2024533933A (en) | Injectable sustained release brexpiprazole formulation and preparation method thereof | |
| CN105687140B (en) | A kind of preparation method of vinpocetine micro mist | |
| CN114306340A (en) | Preparation method and application of cholic acid-quaternized chitosan oligosaccharide-ES 2 peptide/camptothecin conjugate | |
| CN114432250B (en) | Method for stabilizing amorphous fusidic acid | |
| CN116098872B (en) | A kind of long-acting microsphere of apixaban for injection and preparation method thereof | |
| CN115531349B (en) | A bioadhesive nanoparticle combined with PEG network drug delivery system for treating bacterial conjunctivitis and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |